VIDEO: ‘Interesting’ Lung-MAP substudy data at ASCO
In this video, Jia Luo, MD, highlighted a phase 2 randomized study in non-small cell lung cancer presented at ASCO Annual Meeting.
“What was interesting was the patients were randomized to pembrolizumab (Keytruda, Merck) plus ramucirumab (Cyramza, Eli Lilly), which is a VGEF inhibitor, vs. standard-of-care chemotherapy,” Luo, thoracic medical oncologist and cancer researcher with Dana-Farber and Harvard Medical School, said.
- Reckamp KL, et al. Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.